Mabwell (Shanghai) Bioscience Co., Ltd. (SHA:688062)
China flag China · Delayed Price · Currency is CNY
37.20
-0.68 (-1.80%)
Apr 21, 2026, 3:00 PM CST

SHA:688062 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
658.69199.62127.6827.615.88
Other Revenue
3.820.160.150.130.35
662.52199.78127.8427.7316.23
Revenue Growth (YoY)
231.62%56.28%361.03%70.88%206.03%
Cost of Revenue
75.7334.487.32.015.22
Gross Profit
586.79165.3120.5325.7211
Selling, General & Admin
493.83405.2368.36267.62189.16
Research & Development
976.96782.87835.78758.61622.51
Other Operating Expenses
6.814.423.81.880.8
Operating Expenses
1,4791,1931,2081,028812.44
Operating Income
-891.85-1,027-1,087-1,002-801.44
Interest Expense
-90.85-57.78-13.35-10.3-6.41
Interest & Investment Income
7.6120.9246.8845.757.38
Currency Exchange Gain (Loss)
-3.550.28-0.010.16-0.24
Other Non Operating Income (Expenses)
3.29-6.22-1.74-1.822.63
EBT Excluding Unusual Items
-975.36-1,070-1,056-968.59-798.07
Gain (Loss) on Sale of Investments
-8.48-3.73-4.691.08-0.23
Gain (Loss) on Sale of Assets
0.1-0.11-0.010.332.06
Asset Writedown
---3.56--
Other Unusual Items
27.3426.388.619.0623.54
Pretax Income
-956.39-1,047-1,055-958.13-772.7
Income Tax Expense
15.86-0.913.52--
Earnings From Continuing Operations
-972.26-1,047-1,059-958.13-772.7
Minority Interest in Earnings
2.922.655.382.893.11
Net Income
-969.33-1,044-1,053-955.23-769.59
Net Income to Common
-969.33-1,044-1,053-955.23-769.59
Shares Outstanding (Basic)
399400399391299
Shares Outstanding (Diluted)
399400399391299
Shares Change (YoY)
-0.27%0.24%1.93%30.74%5.32%
EPS (Basic)
-2.43-2.61-2.64-2.44-2.57
EPS (Diluted)
-2.43-2.61-2.64-2.44-2.57
Free Cash Flow
-447.93-1,287-1,283-1,264-639.91
Free Cash Flow Per Share
-1.12-3.22-3.21-3.23-2.14
Gross Margin
88.57%82.74%94.29%92.75%67.81%
Operating Margin
-134.62%-514.17%-850.65%-3615.06%-4939.16%
Profit Margin
-146.31%-522.53%-824.05%-3445.00%-4742.85%
Free Cash Flow Margin
-67.61%-643.96%-1003.35%-4559.01%-3943.69%
EBITDA
-710.88-914.86-1,013-937.96-739.4
EBITDA Margin
-107.30%----
D&A For EBITDA
180.97112.3674.4364.4362.04
EBIT
-891.85-1,027-1,087-1,002-801.44
EBIT Margin
-134.62%----
Revenue as Reported
662.52199.78127.8427.7316.23
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.